Advertisement
U.S. markets closed
  • S&P 500

    5,137.08
    +40.81 (+0.80%)
     
  • Dow 30

    39,087.38
    +90.98 (+0.23%)
     
  • Nasdaq

    16,274.94
    +183.04 (+1.14%)
     
  • Russell 2000

    2,076.39
    +21.55 (+1.05%)
     
  • Crude Oil

    79.81
    -0.16 (-0.20%)
     
  • Gold

    2,091.60
    -4.10 (-0.20%)
     
  • Silver

    23.34
    -0.02 (-0.08%)
     
  • EUR/USD

    1.0845
    +0.0038 (+0.35%)
     
  • 10-Yr Bond

    4.1800
    -0.0720 (-1.69%)
     
  • GBP/USD

    1.2660
    +0.0034 (+0.27%)
     
  • USD/JPY

    149.9010
    -0.0830 (-0.06%)
     
  • Bitcoin USD

    62,714.04
    +742.07 (+1.20%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,682.50
    +52.48 (+0.69%)
     
  • Nikkei 225

    39,910.82
    +744.62 (+1.90%)
     

UPDATE 1-Eisai shares plunge in Tokyo after report of death in Alzheimer's trial

(Closes shares in 4th paragraph, adds Eisai statement in 5th.)

TOKYO, Nov 29 (Reuters) - Shares in Japanese drugmaker Eisai Co fell more than 6% on Tuesday after a report that a woman in a trial of the company's Alzheimer's disease treatment died.

A woman receiving lecanemab, an experimental drug developed by Eisai and its U.S. partner Biogen Inc, recently died from a brain haemorrhage, research paper publisher Science.org reported on Sunday.

That would mark a second fatality in a lecanemab trial, following the death of a man in his 80s in June, according to a report by the health journal STAT.

Eisai's shares sank 6.2% to 8,988 yen, leading decliners on the benchmark Nikkei index, which closed 0.5% lower. Shares in Biogen sank 4.3% on Monday.

Eisai said in a statement all available safety information indicates lecanemab therapy is not associated with an increased risk of death overall. The company will present Phase 3 trial results later on Tuesday.

Biogen did not immediately respond to a request for comment.

Eisai and Biogen shares have been on a roller coaster in recent years on prospects for their candidates to battle dementia.

The companies' previous drug Aduhelm won approval from the U.S. Food and Drug Administration in 2021, but its use has been limited due to concerns over its price and effectiveness.

Lecanemab was shown to slow cognitive and functional decline in a large trial of patients in the early stages of Alzheimer's disease, Eisai and Biogen said in September. (Reporting by Rocky Swift in Tokyo and Raghav Mahobe and Khushi Mandowara in Bengaluru; Editing by Cynthia Osterman)

Advertisement